Home › NDC Lookup › Ingredients › Pseudoephedrine Hcl › 45802-0432-62
⚪image loading
(from DailyMed)

pseudoephedrine hydrochloride Pseudoephedrine HCl 30 mg Tablet, Film Coated

by Padagis Israel Pharmaceuticals Ltd · 24 BLISTER PACK in 1 CARTON (45802-432-62) / 1 TABLET, FILM COATED in 1 BLISTER PACK
NDC 45802-0432-62
🏷️ FDA NDC (as labeled) 45802-432-62 billing pads the product segment with a zero
OTC On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 45802-432-62
Product NDC 45802-432
11-digit billing NDC 45802043262
NCPDP billing unit EA — each (per item)
RxCUI 1049160
UNII 6V9V2RYJ8N
Application # M012
SPL Set ID 458594e1-8d99-4de3-8923-2fd8ce2fc406
Established class (EPC) alpha-Adrenergic Agonist
Mechanism of action Adrenergic alpha-Agonists
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2008-10-17
Route ORAL
Dosage form TABLET, FILM COATED
Substance PSEUDOEPHEDRINE HYDROCHLORIDE
GPI-14 42101020100305
GPI class Pseudoephedrine HCl
GCN Seq No 005089
GCN 20481
HICL code 002091
Ingredient (HICL) Pseudoephedrine Hcl
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B6
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Cont3)
HIC3 code B6V
Therapeutic class — specific (HIC3) Decongestants, Oral
AHFS code 12:12.12.00
AHFS class Alpha- And Beta-Adrenergic Agonists
FDB label name PSEUDOEPHEDRINE 30 MG TABLET
FDB brand name Pseudoephedrine Hcl
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 45802-432-62 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0432-62. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the alpha-Adrenergic Agonist class.

Pharmacologic class alpha-Adrenergic Agonist
Drug family (ATC) Sympathomimetics
How it works Adrenergic alpha-Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
FDA applicationM012 (OTC MONOGRAPH DRUG)
Labeler code45802
First marketedOct 2008
Product typeHuman Otc Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name PSEUDOEPHEDRINE 30 MG TABLET Ingredient Pseudoephedrine Hcl
📖 What it is MedlinePlus · NLM

Pseudoephedrine is used to relieve nasal congestion caused by colds, allergies, and hay fever. It is also used to temporarily relieve sinus congestion and pressure. Pseudoephedrine will relieve symptoms but will not treat the cause of the symptoms or speed recovery. Pseudoephedrine is in a class of medications called nasal decongestants. It works by causing narrowing of the blood vessels in the nasal passages.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Pseudoephedrine is a decongestant — it works to temporarily shrink the swollen blood vessels inside your nasal passages and sinuses, which helps open things up so you can breathe m...
  • What exactly does pseudoephedrine do for my congestion?
  • Yes, it does. The regular tablets and Zephrex D capsules are taken every 4 to 6 hours, while extended-release tablets like Sudafed Sinus Congestion 12 Hour or Good Sense Suphedrine...
  • Does it matter which product or form I pick?
📖 Read our full Pseudoephedrine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII R12CBM0EIZ
    A natural wax derived from a Brazilian palm tree, used as a coating and polish on tablets and capsules. It creates a smooth, shiny finish that protects the medicine and improves appearance.
  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII 6T47AS764T
    Red 40 Lake is a synthetic colorant made by combining Red 40 dye with aluminum hydroxide. It's used to give tablets, capsules, and other medicines a red or pink color for identification and appearance.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 3WJQ0SDW1A
    Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
  • UNII 6OZP39ZG8H
    Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

10 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescarnauba wax, dibasic calcium phosphate dihydrate, FD&C red no. 40 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, silicon dioxide, titanium dioxide

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.078 $1.87 / 24 tablet
Medicaid paysCMS SDUD · 12 mo $0.2102 $5.04 / 24 tablet
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.078 $0.048
▲ Up 54% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Good Sense Nasal Decongestant 30 mg 00113-0432-62 L. 24 tablets $0.078 — Availability likely —
Nasal Decongestant 30 mg 00536-3607-35 Rugby 24 tablets $0.078 — Availability likely —
SudoGest 30 mg 00904-5053-59 Major 100 tablets $0.078 — Availability likely —
SudoGest Nasal Decongestant 30 mg 00904-6337-24 Major 1 tablet $0.078 — Availability likely —
SudoGest 30 mg 00904-6727-60 Major 100 tablets $0.078 — Availability likely —
Pseudoephedrine HCl 30 mg 00904-6990-61 Major 10 tablets $0.078 — Availability likely —
pseudoephedrine hydrochloride 30 mgthis 45802-0432-62 Padagis 1 tablet $0.078 — Availability likely —
Nasal Decongestant Maximum Strength, Non-Drowsy 30 mg 46122-0428-62 Amerisource 24 tablets $0.078 — Availability likely —
Leader Nasal Decongestant 30 mg 70000-0002-01 Cardinal 1 tablet $0.078 — Availability likely —
Nasal Decongestant Maximum Strength 30 mg 70677-1017-01 Strategic 24 tablets $0.078 — Availability likely —
Nasal Decongestant D 30 mg 00363-1214-08 Walgreen 24 tablets — — FDA listed —
Sinus Pressure and Congestion Relief Maximum Strength 30 mg 11822-0112-02 Rite 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 21130-0112-08 Better 24 tablets — — FDA listed —
sinus 30 mg 30142-0613-62 Kroger 1 tablet — — Discontinued —
Sinus Decongestion 30 mg 30142-0641-08 Kroger 24 tablets — — FDA listed —
Topcare Nasal Decongestant Maximum Strength Non Drowsy 30 mg 36800-0432-62 Topco 1 tablet — — FDA listed —
Nasal Decongestant 30 mg 37808-0112-22 H 24 tablets — — FDA listed —
equaline nasal decongestant non drowsy maximum strength 30 mg 41163-0432-67 United 6 tablets — — FDA listed —
nasal decongestant maximum strength non drowsy 30 mg 41250-0432-62 Meijer 1 tablet — — FDA listed —
CareOne Nasal and Sinus Decongestant 30 mg 41520-0881-62 American 12 tablets — — FDA listed —
Sinus and Congestion Non-Drowsy 30 mg 49035-0780-08 Wal-Mart 24 tablets — — FDA listed —
Sudogest 30 mg 50090-1961-00 A-S 28 tablets — — FDA listed —
Sudogest Nasal Decongestant 30 mg 50090-4345-00 A-S 48 tablets — — Discontinued —
pseudoephedrine hydrochloride 30 mg 50090-5615-01 A-S 1 tablet — — FDA listed —
SUDAFED Sinus Congestion 30 mg 50580-0363-01 Kenvue 12 tablets — — FDA listed —
Nasal Decongestant 30 mg 50844-0112-08 L.N.K. 12 tablets — — FDA listed —
Sinus and Nasal Decongestant 30 mg 51316-0121-22 CVS 24 tablets — — FDA listed —
Sinus And Nasal Decongestant 30 mg 51316-0317-62 CVS 12 tablets — — FDA listed —
Nasal Decongestant 30 mg 56062-0432-62 Publix 24 tablets — — FDA listed —
Nasal Decongestant Non-Drowsy 30 mg 59779-0112-08 CVS 24 tablets — — FDA listed —
Nasal Decongestant 30 mg 59779-0432-62 CVS 1 tablet — — FDA listed —
Nasal Decongestant 30 mg 63187-0344-24 Proficient 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 63868-0802-24 CHAIN 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 68016-0473-24 Chain 24 tablets — — FDA listed —
pseudoephedrine hydrochloride 30 mg 71205-0197-24 Proficient 1 tablet — — FDA listed —
Sinus Congestion 30 mg 83324-0054-24 Chain 24 tablets — — FDA listed —
pseudoephedrine hydrochloride 30 mg 85766-0049-24 Sportpharm 1 tablet — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2008
On the market since
Oct 2008
📍
2026
Currently FDA-listed
18 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 45802-0432-62, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
21.4K
Units reimbursed last 4 qtrs
677.2K
Gross reimbursed last 4 qtrs
$142.4K
Avg / prescription
$6.67
Avg / unit
$0.2102
Latest quarter Q4 2025
5.2KRx
Medicaid pays / ea
$0.2102
gross reimbursed
vs
NADAC / ea
$0.0780
acquisition cost
=
Spread
+$0.1322
+169% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
42% FFS 58% MCO
Fee-for-service · 8,946 Rx Managed care · 12,406 Rx
State Medicaid map
Alaska: no data reported AK Maine: 4,266 units · 306 per 100k residents ME Washington: 25,347 units · 324 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 12,861 units · 224 per 100k residents MN Wisconsin: 11,354 units · 192 per 100k residents WI Michigan: 3,660 units · 36.5 per 100k residents MI New York: 238,455 units · 1,218 per 100k residents NY Vermont: no data reported VT New Hampshire: 342 units · 24.4 per 100k residents NH Oregon: 21,210 units · 501 per 100k residents OR Nevada: 10,720 units · 336 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 5,070 units · 158 per 100k residents IA Illinois: 7,426 units · 59.2 per 100k residents IL Indiana: 884 units · 12.9 per 100k residents IN Ohio: 60,123 units · 510 per 100k residents OH Pennsylvania: 25,959 units · 200 per 100k residents PA New Jersey: 35,622 units · 383 per 100k residents NJ Massachusetts: 19,833 units · 283 per 100k residents MA California: 509 units · 1.3 per 100k residents CA Utah: 693 units · 20.3 per 100k residents UT Colorado: no data reported CO Nebraska: 9,271 units · 469 per 100k residents NE Missouri: no data reported MO Kentucky: 64,984 units · 1,436 per 100k residents KY West Virginia: 912 units · 51.5 per 100k residents WV Virginia: 22,379 units · 257 per 100k residents VA Maryland: 7,035 units · 114 per 100k residents MD Connecticut: 528 units · 14.6 per 100k residents CT Rhode Island: 9,591 units · 876 per 100k residents RI Arizona: 20,935 units · 282 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 20,303 units · 285 per 100k residents TN North Carolina: no data reported NC South Carolina: 2,222 units · 41.4 per 100k residents SC Delaware: 2,399 units · 233 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: 6,565 units · 223 per 100k residents MS Alabama: no data reported AL Georgia: 333 units · 3.0 per 100k residents GA D.C.: 2,033 units · 299 per 100k residents DC Hawaii: 15,904 units · 1,108 per 100k residents HI Texas: 7,507 units · 24.6 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
1.31,436
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 1,436 /100k
2 New York 1,218 /100k
3 Hawaii 1,108 /100k
4 Rhode Island 876 /100k
5 Ohio 510 /100k
6 Oregon 501 /100k
7 Nebraska 469 /100k
8 New Jersey 383 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
45802-0432-62 You're viewing this 24 BLISTER PACK in 1 CARTON (45802-432-62) / 1 TABLET, FILM COATED in 1 BLISTER PACK 2008-10-17 Active

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose
🎯 Indications and Usage 25 words ▾

Uses • temporarily relieves sinus congestion and pressure • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies

⏱️ Dosage and Administration 70 words ▾

Directions adults and children 12 years and over • take 2 tablets every 4 to 6 hours • do not take more than 8 tablets in 24 hours children ages 6 to 11 years • take 1 tablet every 4 to 6 hours • do not take more than 4 tablets in 24 hours children under 6 years do not use this product in children under 6 years of age

⚠️ Warnings 152 words ▾

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have • heart disease • high blood pressure • thyroid disease • diabetes • trouble urinating due to an enlarged prostate gland When using this product do not exceed recommended dosage Stop use and ask a doctor if • nervousness, dizziness, or sleeplessness occur • symptoms do not improve within 7 days or occur with a fever If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📦 Storage and Handling 33 words ▾

Other information • each tablet contains: calcium 20 mg • store at 20 ° -25 ° C (68 ° -77 ° F) • do not use if blister unit is broken or torn

🧪 Active Ingredient 9 words ▾

Active ingredient (in each tablet) Pseudoephedrine HCl 30 mg

🧪 Inactive Ingredients 27 words ▾

Inactive ingredients carnauba wax, dibasic calcium phosphate dihydrate, FD&C red no. 40 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, silicon dioxide, titanium dioxide

🎯 Purpose 3 words ▾

Purpose Nasal decongestant

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 45802-0423-35 · Padagis 45802-0433-21 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.